Biofidelity has closed a £17.3m Series A+ funding round led by led by Octopus Ventures and SBI Investment Co Ltd.
The capital will be used to commercialise Biofidelity’s ASPYRE technology, a high sensitivity molecular diagnostic platform and the first assay for high sensitivity diagnosis of non-small-cell-lung-cancer. This is will include launch in North America.
The funding will also be used to expand and validate Biofidelity’s technology platform on other key oncology applications where access to high sensitivity precision diagnostics is key to improving outcomes.
ONI has closed a $75m Series B financing led by US investors ARCH Venture Partners and Casdin Capital.
ONI is a pioneer in observing single molecules in living cells. The Company’s first product, the Nanoimager, is the world’s first desktop, super-resolution, single-molecule imaging platform capable of visualising and tracking individual molecules in complex systems such as nanoparticles, living cells and tissue with 20nm resolution.
The Series B funds will be used to build a product portfolio that harnesses the Company’s innovative technology to unlock new possibilities in therapeutic and diagnostic development, as well as basic life sciences research.
OrganOx Ltd. is commercialising the metra L, the world’s first normothermic liver perfusion device.
OTIF’s investment was advised by Oxford Investment Consultants LLP and was part of a £6.4 million round led by Oxford Investment Consultants LLP.
Funding will accelerate a number of programmes in OrganOx’s R&D pipeline, with a Phase I clinical trial for a normothermic kidney perfusion device due to start later this year.
This investment in OrganOx Ltd., brings the total funds invested by OTIF in the Company to £5.6m.
Oxford Endovascular Ltd is commercialising OxiFlow™, a novel blood flow diversion device (‘stent’) for treating Intracranial Aneurysms (ICAs).
OTIF’s investment was advised by Oxford Investment Consultants LLP and was part of a $10m Series A funding round led by Vulpes Investment Management, a Singapore-based life sciences investor.
This is the second OTIF investment in Oxford Endovascular to date, bringing total funds invested by the fund in the Company to £500k.
